Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: Possible markers for and potential insights into the pathoetiology of Parkinson's disease

Journal of Neural Transmission

Volumn 103, Issue 4, 1996, Pages 433-446

  Cheng, F C ^a  

^a Department of Medical Research   (Taiwan)

Author keywords

5 s cysteinyldopamine; Cerebrospinal fluid; Homovanillic acid; Parkinson's disease

Indexed keywords

CYSTEINE; CYSTEINYLDOPA; DOPAMINE; GLUTATHIONE; HOMOVANILLIC ACID; LEVODOPA; NEUROMELANIN;

AGED; AMINO ACID TRANSPORT; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; ELECTROCHEMICAL DETECTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

AGED; ANTIPARKINSON AGENTS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; FEMALE; HOMOVANILLIC ACID; HUMANS; LEVODOPA; MALE; PARKINSON DISEASE; REFERENCE VALUES;

EID: 0029878379     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01276419     Document Type: Article

References (24)

1. Adolfsson R, Gottfries CG, Roos BE, Winblad BJ (1979) Postmortem distribution of DA and homovanillic acid in human brain, variations related to age, and a review of the literature. J Neural Transm 45: 81-105
2. Bernheimer H, Hornykiewicz O (1965) Herabgesetzte Konzentration der Homovanillinsäure im Gehirn von Parkinsonkranken Menschen als Ausdruck der Störung des zentralen Dopaminstoffwechsels. Klin Wochenschr 39: 1056-1059
3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 20: 415-455
4. Calabrese V, Fariello RG (1988) Regional distribution of malonaldehyde in mouse brain. Biochem Pharmacol 37: 2287-2288
5. Carlsson A, Fornstedt B (1991) Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson's disease. Neurology 41 [Suppl 2]: 50-52
6. Carstam R, Brinck C, Hindemith-Augustsson A, Rorsman H, Rosengren E (1991) The neuromelanin of the human substantia nigra. Biochim Biophys Acta 1097: 152-160
7. Cheng F-C, Juo J-S, Shih Y, Lai JS, Ni DR, Chia LG (1993a) Simultaneous measurement of serotonin, catecholamines and their metabolites in mouse brain homogenates by high-performance liquid chromatography with a microbore column and dual electrochemical detection. J Chromatogr 615: 225-236
8. Cheng F-C, Tsai MH, Cheng WY, Kuo JS, Jen J-F, Liu TS (1993b) Rapid and improved simultaneous measurement of serotonin, catecholamines, and their metabolites in mouse brain homogenates by HPLC with a dual amperometric detector. J Biomed Lab Sci 5: 165-180
9. Chia L-G, Cheng F-C, Kuo J-S (1993) Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease. J Neurol Sci 116: 125-134
10. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389
11. Fariello RG, Ghilardi O, Peschechera A, Ramucci MT, Angelucci T (1988) Regional distribution of ubiquinones and tocopherols in the mouse brain: lowest content of ubiquinols in the substantia nigra. Neuropharmacology 27: 1077-1080
12. Fornstedt B, Rosengren E, Carlsson A (1986) Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, DOPA and DOPAC in the brains of eight mammalian species. Neuropharmacology 25: 451-454
13. Fornstedt B, Carlsson A (1989) A marked rise in 5-S-cysteinyl-dopamine levels in guineapig striatum following reserpine treatment. J Neural Transm 76: 155-161
14. Fornstedt B, Brun A, Rosengren E, Carlsson A (1989) The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm [P-D Sect] 1: 279-295
15. Gibb WRG, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51: 757
16. Gonzalez-Quevedo Garcia JC, Fernandez R, Fernandez L (1993) Monoamine metabolites in normal human cerebrospinal fluid and in degenerative disease of the central nervous system. Bol Estud Med Biol 41: 13-19
17. Graham DG (1978) Oxidation pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633-643
18. Graham DG, Tiffany SM, Bell WR, Gutnecht WF (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds towards C1300 neuroblastoma cells in vitro. Mol Pharmacol 14: 644-653
19. Halliwell B, Gutteridge MC (1984) Oxygen toxicity, oxygen radicals, transition metal ions and disease. Biochem J 219: 1-14
20. Hartikainen P, Reinikanee KJ, Soininen H, Sirvio J, Soikkei R, Riekkinen PJ (1992) Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls. J Neural Transm [P-D Sect] 4: 53-68
21. Hornykiewicz O (1982) Imbalance of brain monoamines and clinical disorders. Prog Brain Res 55: 419-429
22. Hornykiewicz O (1989) Aging and neurotoxins as causitive factors in idiopathic Parkinson's disease - a critical analysis of neurochemical evidence. Prog Neuropsychopharmacol Biol Psychiatry 13: 319-328
23. Hornykiewicz O, Kish SJ (1986) Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45: 19-34
24. Jellinger K (1986) An overview of morphological changes in Parkinson's disease. Adv Neurol 45: 1-16